Want to see IRON full AI Analyst Report?
Top Page
Disc Medicine
(NASDAQ:IRON)
Select Model
Select Model
Rating:68Neutral
Price Target:
$91.00
▲(10.42% Upside)
Action:Reiterated
Date:10/22/26
The score is led by strong recent corporate catalysts (pivotal Phase 3 success and extended funding runway) and constructive technical momentum. Offsetting these positives, financial performance remains pressured by no revenue, widening losses, and heavy cash burn, while valuation support is limited given negative earnings and no dividend.
Positive Factors
Pivotal clinical validation
Bitopertin’s pivotal Phase 3 success materially strengthens Disc Medicine’s lead program and supports planned FDA NDA resubmission by the end of 2026. Positive efficacy, safety, and quality-of-life results improve the probability of regulatory progress and potential future commercialization.
Negative Factors
No revenue base
Disc Medicine has not yet established commercial revenue or demonstrated operating leverage, so its financial performance remains dependent on development progress rather than product sales. Until a therapy is approved and launched, the company cannot fund operations through recurring customer revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal clinical validation
Bitopertin’s pivotal Phase 3 success materially strengthens Disc Medicine’s lead program and supports planned FDA NDA resubmission by the end of 2026. Positive efficacy, safety, and quality-of-life results improve the probability of regulatory progress and potential future commercialization.
Read all positive factors
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.19B
Dividend YieldN/A
Average Volume (3M)1.18M
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth-47.00%
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.60
Shares Outstanding38,392,845
10 Day Avg. Volume2,237,822
30 Day Avg. Volume1,180,861
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.99
Forecast
1Y Price Target
$122.20Price Target Upside48.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.32
Revenue Forecast (FY)N/A
Disc Medicine Business Overview & Revenue Model
Company Description
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from se...
Disc Medicine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -241.67M | -207.94M | -108.27M | -76.23M | -46.74M | -33.78M |
| Net Income | -245.89M | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | ||||||
| Total Assets | 735.07M | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 717.75M | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 60.86M | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 90.91M | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 644.16M | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | ||||||
| Free Cash Flow | -197.58M | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -197.54M | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -93.42M | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 262.30M | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Positive
82.41
Price Trends
71.27
Positive
73.07
Positive
70.63
Positive
Market Momentum
3.10
Negative
69.93
Neutral
92.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Positive. The current price of 82.41 is above the 20-day moving average (MA) of 67.41, above the 50-day MA of 71.27, and above the 200-day MA of 70.63, indicating a bullish trend. The MACD of 3.10 indicates Negative momentum. The RSI at 69.93 is Neutral, neither overbought nor oversold. The STOCH value of 92.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRON.
Disc Medicine Risk Analysis
Disc Medicine disclosed 82 risk factors in its most recent earnings report. Disc Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Disc Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $947.82M | 2.87 | 96.49% | ― | 3.31% | 221.64% | |
68 Neutral | $3.19B | -12.61 | -37.17% | ― | ― | -47.00% | |
58 Neutral | $1.29B | 9.36 | -109.40% | ― | ― | ― | |
55 Neutral | $2.28B | -5.44 | -35.67% | ― | 140.58% | -161.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $622.24M | -9.71 | -30.31% | ― | 24.39% | 21.06% |
* Healthcare Sector Average
IRON
Disc Medicine
83.20
-1.80
-2.12%
GERN
Geron
0.97
-0.26
-21.30%
OMER
Omeros
17.88
10.20
132.81%
RIGL
Rigel
50.74
21.34
72.59%
AGIO
Agios Pharma
38.12
-3.84
-9.15%
COAG
Hemab Therapeutics Holdings, Inc.
38.50
4.50
13.24%
Disc Medicine Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Disc Medicine completes major common stock offering
Positive
Oct 22, 2026
On October 20, 2026, Disc Medicine entered into an underwriting agreement for an underwritten public offering of 6,000,000 shares of common stock at $75.00 per share, with underwriters granted a 30-day option to purchase up to an additional 900,00...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Disc Medicine reports pivotal success in APOLLO bitopertin trial
Positive
Oct 19, 2026
On October 19, 2026, Disc Medicine reported positive topline data from its pivotal Phase 3 APOLLO trial of bitopertin in adults and adolescents with erythropoietic protoporphyria and X-linked protoporphyria. The randomized, double-blind study enro...
Business Operations and Strategy
Disc Medicine reports promising DISC-3405 Phase 2 data
Positive
Sep 10, 2026
On September 9, 2026, Disc Medicine presented initial data from its Phase 2 RESTORE-PV trial of DISC-3405 in patients with polycythemia vera at the Society of Hematologic Oncology annual meeting. In Cohort A, the investigational antibody increased...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.